
|Videos|July 15, 2020
The Evolving Role of Tucatinib in HER2-Positive Metastatic Breast Cancer
Author(s)Sara A. Hurvitz, MD
A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5







































